Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial

Table 2 Relationship between risk factors and the incidence of VTE

Variables	N	Venous thromboembolism		P
Variables	N	No.	%	P
Interventional groups
Control	2340	9	0.384	0.017*
Bemiparin	2340	1	0.042
Enoxaparin	2340	2	0.085
Age (years)
≤35	4366	8	0.18	1*
>35	2654	4	0.15	1*
BMI (Kg/m²)
<25	586	3	0.5	0.003*
25-29	2680	0	0
30+	3754	9	0.2
Risk of APS
No	7018	12	0.2	1*
Yes	2	0	0	1*
Varicose veins
No	6925	12	0.2	1*
Yes	95	0	0	1*
Heart Disease
No	7001	12	0.2	1*
Yes	19	0	0	1*
Surgery during pregnancy
No	6936	12	0.2	1*
Yes	84	0	0	1*
Dehydration
No	6990	12	0.2	1*
Yes	30	0	0	1*
Severe inflammation
No	6989	12	0.2	1*
Yes	31	0	0	1*
Pre-eclampsia
No	6625	10	0.2	0.144*
Yes	395	2	0.5	0.144*
Prolonged labour
No	6525	10	0.15	0.206*
Yes	495	2	0.4	0.206*
Smoking
No	6911	12	0.17	1*
Yes	109	0	0	1*
Twin pregnancy
No	6839	11	0.16	0.269*
Yes	181	1	0.55	0.269*
PPH
No	6951	12	0.17	1*
Yes	69	0	0	1*
Bed rest
No	6988	12	0.17	1*
Yes	32	0	0	1*
Wound infection
No	6984	12	0.17	1*
Yes	36	0	0
Pyelonephritis
No	6947	12	0.17	1*
Yes	73	0	0	1*
IVF

*Analysed by Fisher’s exact test.
BMI: body mass index; APS:antiphospholipid antibody syndrome; PPH: postpartum haemorrhage; IVF: in vitro fertilisation.

ISSN: 1471-2393